Simplify Asset Management’s SAB Biotherapeutics SABS Stock Holding History

Simplify Asset Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$409K	Sell	104,849 -82,381	-44%	-$307K	0.01%	119
2026 Q1	$717K	Sell	187,230 -20,997	-10%	-$83.7K	0.01%	89
2025 Q4	$779K	Buy	+208,227	New	+$685K	0.01%	93

Other funds holding SABS

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Simplify Asset Management's SABS Position: Q2 2026 in Review

Simplify Asset Management reduced its SAB Biotherapeutics (SABS) stake by 44% in Q2 2026, selling an estimated $307K and leaving 104,849 shares worth $409K. The position accounts for 0.01% of the portfolio, ranked #119.

Simplify Asset Management first reported a position in SABS in Q4 2025 and has held it in 3 quarters since. The position peaked at $779K in Q4 2025. 2 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

Simplify Asset Management held 104,849 shares of SAB Biotherapeutics worth $409K as of Q2 2026.
Simplify Asset Management sold 82,381 SAB Biotherapeutics shares in Q2 2026, an estimated $307K.
SAB Biotherapeutics made up 0.01% of Simplify Asset Management's portfolio in Q2 2026, its #119 holding.
Simplify Asset Management first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
Simplify Asset Management's SAB Biotherapeutics position peaked at $779K in Q4 2025.
2 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Simplify Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.